IMPT halves pelvic bone marrow dose in anal cancer treatment planning

In ten anal cancer cases, IMPT reduced mean pelvic marrow dose from 24.3 to 12.3 Gy, but clinical toxicity reduction remains unproven.

KEY POINTS

  • This retrospective single-center dosimetric study from Tata Memorial Centre, India, evaluated 10 patients with anal canal squamous cell carcinoma previously treated with photon-based VMAT in 2023. Patients had cT2–T4, N0–N2, M0 disease, and the clinical photon plans were retrospectively compared with newly generated intensity-modulated proton therapy (IMPT) plans using the same target and OAR contours.
  • Photon treatment delivered 45 Gy to the elective pelvis, with a simultaneous integrated boost to 55–57 Gy for primary disease and involved nodes, predominantly using capecitabine and mitomycin C. IMPT planning used a four-field arrangement with bilateral anterior and posterior oblique beams, robust optimization with 5-mm setup and 3.5% range uncertainty, and a fixed proton RBE of 1.1. Target coverage and robustness were prioritized over additional OAR sparing.
  • Target coverage improved with IMPT, particularly for elective pelvic and boost volumes. Mean pelvic CTV V95% increased from 97.75% with photon IMRT to 99.98% with IMPT (p<0.001), while V100% increased from 72.37% to 91.74% (p<0.001). For the primary tumor boost CTV, V100% improved from 67.99% to 86.80% (p=0.024), with better reported dose homogeneity and conformity.
  • The largest dosimetric advantage involved pelvic bone marrow sparing. Mean marrow dose decreased from 24.27 Gy with IMRT to 12.30 Gy with IMPT, an absolute reduction of 11.97 Gy (p<0.001). Marrow V10Gy, V20Gy and V30Gy decreased by 41.51, 30.77 and 15.78 percentage points, respectively (all p<0.001), while differences at 40–45 Gy were smaller and not statistically significant.
  • IMPT also reduced low- and intermediate-dose exposure to the bowel, bladder and external genitalia. Bowel V30Gy decreased by 44.71% (p=0.03) and V35Gy by 37.03% (p=0.05), while bladder V35Gy decreased by 17.33 percentage points (p=0.009). External genitalia V10Gy, V20Gy and V30Gy decreased by 53.17, 33.28 and 17 percentage points, respectively (all p<0.01). Differences at higher dose levels, approximately 40–50 Gy, were generally not statistically significant.
  • Based on achievable IMPT doses, the authors proposed preliminary planning objectives and more permissive trial thresholds, derived using the observed mean plus one or two standard deviations. Examples include bone marrow mean dose ≤13.5 Gy as an optimal objective and ≤15 Gy as a trial threshold, bowel V30Gy ≤130 cc and ≤170 cc, bladder V35Gy ≤26% and ≤30%, and external genitalia V20Gy ≤10% and ≤20%, respectively. These are study-derived feasibility objectives rather than validated dose-toxicity constraints.
  • The findings remain exclusively dosimetric: none of the ten patients received the simulated IMPT plans, and no proton-related clinical toxicity outcomes were evaluated. The small sample, separate photon and proton planning systems, differences in optimization methods, and sensitivity of proton dose distributions to bowel gas, anatomical changes, setup variation and range uncertainty limit generalizability. The proposed constraints require prospective validation before they can be used to predict reductions in hematologic, gastrointestinal, genitourinary or skin toxicity.

CLINICAL TAKEAWAY

IMPT may substantially reduce low- and intermediate-dose exposure to pelvic bone marrow, bowel, bladder and external genitalia during definitive chemoradiotherapy for anal cancer while maintaining favorable target coverage. The proposed OAR objectives offer a starting point for prospective proton trials, but their clinical value remains unproven, and the potential dosimetric advantages must be balanced against anatomical and range-related uncertainties.

SOURCE

International Journal of Particle Therapy

Browse more research Suggest a correction